Xinhua Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xinhua Li has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Ailin Yang
Department of Head and Neck Oncology Tianjin Medical University Cancer Institute & Hospital Tianjin China
1 shared publicationChao Jing
Department of Head and Neck Oncology Tianjin Medical University Cancer Institute & Hospital Tianjin China
1 shared publication- Chenge Qin
Department of Otorhinolaryngology, Tianjin Medical University General Hospital, Tianjin 300052, China
1 shared publication Hao Li
Department of Head and Neck Oncology Tianjin Medical University Cancer Institute & Hospital Tianjin China
1 shared publication- Huifang Zhou
The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
1 shared publication Jin Zhang
Department of Head and Neck Oncology Tianjin Medical University Cancer Institute & Hospital Tianjin China
1 shared publication
Latest Publications
- Open Access
- 22 December 2025
- Published by Wiley in Head & Neck
- Vol. 48 (5) , 1351-1360
Greater Attention to Gingival Cancer and Floor of Mouth Cancer: Based on a Retrospective Analysis of Oral Cancer Across Different Subsites
Background: The gingiva and floor of the mouth are distinct subsites, and oral squamous cell carcinoma (OSCC) originating in these locations warrants further indepth understanding. Methods: This study enrolled patients with OSCC from 2000 to 2020, and analyzed the clinicopathological characteristics. Kaplan–Meier analysis compared overall survival (OS) and recurrence‐free survival (RFS). Univariate analysis and multivariate Cox proportional hazards model examined the risk factors on survival outcomes. Results: A total of 885 OSCC patients were included, with the most common tumor subsites: oral tongue (41.9%), gingiva (31.8%), and floor of mouth (16.0%). Gingival and floor of mouth showed a higher proportion of advanced stage (65.8%, 66.9%) and significantly poorer OS (3‐year: 63.0%, 57.0%; 5‐year: 49.8%, 37.3%) and RFS (3‐year: 59.1%, 61.3%; 5‐year: 55.5%, 57.0%). Neoadjuvant chemotherapy was associated with significantly reduced mortality in gingival cancer (HR = 0.598), while tobacco exposure (HR = 1.952) was associated with a significant increase in mortality in floor of mouth cancer. Conclusion: Gingival cancer and floor of mouth cancer have a worse prognosis, and thus require greater attention throughout the entire management process.
- 22 December 2025
- Published by Wiley in Head & Neck
- Vol. 48 (5) , 1351-1360
Open AccessGreater Attention to Gingival Cancer and Floor of Mouth Cancer: Based on a Retrospective Analysis of Oral Cancer Across Different Subsites
Background: The gingiva and floor of the mouth are distinct subsites, and oral squamous cell carcinoma (OSCC) originating in these locations warrants further indepth understanding. Methods: This study enrolled patients with OSCC from 2000 to 2020, and analyzed the clinicopathological characteristics. Kaplan–Meier analysis compared overall survival (OS) and recurrence‐free survival (RFS). Univariate analysis and multivariate Cox proportional hazards model examined the risk factors on survival outcomes. Results: A total of 885 OSCC patients were included, with the most common tumor subsites: oral tongue (41.9%), gingiva (31.8%), and floor of mouth (16.0%). Gingival and floor of mouth showed a higher proportion of advanced stage (65.8%, 66.9%) and significantly poorer OS (3‐year: 63.0%, 57.0%; 5‐year: 49.8%, 37.3%) and RFS (3‐year: 59.1%, 61.3%; 5‐year: 55.5%, 57.0%). Neoadjuvant chemotherapy was associated with significantly reduced mortality in gingival cancer (HR = 0.598), while tobacco exposure (HR = 1.952) was associated with a significant increase in mortality in floor of mouth cancer. Conclusion: Gingival cancer and floor of mouth cancer have a worse prognosis, and thus require greater attention throughout the entire management process.
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Expression Pattern and Prognostic Value of EPHA/EFNA in Breast Cancer by Bioinformatics Analysis: Revealing Its Importance in Chemotherapy
The activities of the ephrin family in breast cancer (BrCa) are complex. Family A receptors (EPHA) and ligands (EFNA) can act as oncogenes or tumor suppressors and are implicated in chemoresistance. Here, we examined the expression pattern and prognostic value of the EPHA/EFNA family in patients with breast cancer, including patients with different subtypes or different chemotherapy cohorts. In the UALCAN database, the mRNA expression of EPHA1, EPHA10, EFNA1, EFNA3, and EFNA4 was significantly higher, whereas that of EPHA2, EPHA4, EPHA5, and EFNA5 was significantly lower in breast cancer tissues than in paracancerous tissues. The transcriptional levels of EPHA/EFNA family members were correlated with intrinsic subclasses of breast cancer. The relationship between EPHA/EFNA and the clinicopathological parameters of BrCa was analyzed using bc‐GenExMiner V4.5. EPHA1, EPHA2, EPHA4, EPHA7, EFNA3, EFNA4, and EFNA5 were upregulated in estrogen receptor‐ (ER‐) and progesterone receptor‐ (PR‐) negative tumors, whereas EPHA3, EPHA6, and EFNA1 were upregulated in ER‐ and PR‐positive tumors. EPHA1, EPHA2, EFNA3, and EFNA4 mRNA expression was significantly higher in human epidermal growth factor receptor 2‐ (HER2‐) positive tumors than in HER2‐negative tumors. Triple‐negative status was positively correlated with EPHA1, EPHA2, EPHA4, EPHA7, EFNA3, EFNA4, and EFNA5 and negatively correlated with EPHA3 and EPHA10 mRNA expression. Genetic alterations of EPHA/EFNA in breast cancer varied from 1.1% to 10% for individual genes, as determined by the cBioPortal database. The Kaplan–Meier plotter indicated that high EphA7 mRNA expression was associated with poor overall survival (OS) and recurrence‐free survival (RFS), especially in the HER2 and luminal A subtypes. EFNA4 was predicted to have poor OS and RFS in breast cancers, especially in luminal B, basal‐like subtype, and patients treated with adjuvant chemotherapy. High EPHA3 expression was significantly associated with better OS and RFS, especially in the luminal A subtype, but with poor RFS in BrCa patients receiving chemotherapy. Our findings systematically elucidate the expression pattern and prognostic value of the EPHA/EFNA family in BrCa, which might provide potential prognostic factors and novel targets in BrCa patients, including those with different subtypes or treated with chemotherapy.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessExpression Pattern and Prognostic Value of EPHA/EFNA in Breast Cancer by Bioinformatics Analysis: Revealing Its Importance in Chemotherapy
The activities of the ephrin family in breast cancer (BrCa) are complex. Family A receptors (EPHA) and ligands (EFNA) can act as oncogenes or tumor suppressors and are implicated in chemoresistance. Here, we examined the expression pattern and prognostic value of the EPHA/EFNA family in patients with breast cancer, including patients with different subtypes or different chemotherapy cohorts. In the UALCAN database, the mRNA expression of EPHA1, EPHA10, EFNA1, EFNA3, and EFNA4 was significantly higher, whereas that of EPHA2, EPHA4, EPHA5, and EFNA5 was significantly lower in breast cancer tissues than in paracancerous tissues. The transcriptional levels of EPHA/EFNA family members were correlated with intrinsic subclasses of breast cancer. The relationship between EPHA/EFNA and the clinicopathological parameters of BrCa was analyzed using bc‐GenExMiner V4.5. EPHA1, EPHA2, EPHA4, EPHA7, EFNA3, EFNA4, and EFNA5 were upregulated in estrogen receptor‐ (ER‐) and progesterone receptor‐ (PR‐) negative tumors, whereas EPHA3, EPHA6, and EFNA1 were upregulated in ER‐ and PR‐positive tumors. EPHA1, EPHA2, EFNA3, and EFNA4 mRNA expression was significantly higher in human epidermal growth factor receptor 2‐ (HER2‐) positive tumors than in HER2‐negative tumors. Triple‐negative status was positively correlated with EPHA1, EPHA2, EPHA4, EPHA7, EFNA3, EFNA4, and EFNA5 and negatively correlated with EPHA3 and EPHA10 mRNA expression. Genetic alterations of EPHA/EFNA in breast cancer varied from 1.1% to 10% for individual genes, as determined by the cBioPortal database. The Kaplan–Meier plotter indicated that high EphA7 mRNA expression was associated with poor overall survival (OS) and recurrence‐free survival (RFS), especially in the HER2 and luminal A subtypes. EFNA4 was predicted to have poor OS and RFS in breast cancers, especially in luminal B, basal‐like subtype, and patients treated with adjuvant chemotherapy. High EPHA3 expression was significantly associated with better OS and RFS, especially in the luminal A subtype, but with poor RFS in BrCa patients receiving chemotherapy. Our findings systematically elucidate the expression pattern and prognostic value of the EPHA/EFNA family in BrCa, which might provide potential prognostic factors and novel targets in BrCa patients, including those with different subtypes or treated with chemotherapy.